We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Fecal Analyses Leads to Inflammatory Bowel Disease Diagnosis

By LabMedica International staff writers
Posted on 23 Feb 2016
Print article
The Clarus 500 gas chromatography mass spectrometry (GC-MS)
The Clarus 500 gas chromatography mass spectrometry (GC-MS) (Photo courtesy of Perkin Elmer)
The development of sophisticated analytical techniques has enabled the study and interpretation of changes in the fecal volatile organic metabolites and its correlation with the pathophysiological mechanisms in the gut during health and disease.

The etiology of inflammatory bowel disease (IBD) remains poorly understood, but recent evidence suggests an important role of gut microbial dysbiosis (also called dysbacteriosis, a term for a microbial imbalance on or inside the body) in IBD, and this may be associated with changes in fecal volatile organic metabolites (VOMs).

Gastroenterologists at the University Hospital Southampton (UK) and their colleagues obtained fecal samples from 117 people with Crohn's disease (CD), 100 with ulcerative colitis (UC), and 109 healthy controls. Fecal VOMs were extracted using solid-phase micro-extraction and analyzed by gas chromatography mass spectrometry. Data analysis was carried out using partial least squares-discriminate analysis (PLS-DA) to determine class membership based on distinct metabolomic profiles.

Fecal samples were submitted within six hours of bowel movement. A 2-gram aliquot was placed into 18-mL headspace vial (Supelco; Poole, UK). The VOMs were thermally desorbed by immediately transferring the fiber into the heated injection port (220 °C) of a Clarus 500 gas chromatography mass spectrometry (GC-MS, PerkinElmer; Beaconsfield, UK). The GC-MS generated a chromatogram with peaks representing individual compounds.

The scientists used the PLS-DA model to show clear separation of active CD from inactive disease and healthy controls. Heptanal, 1-octen-3-ol, 2-piperidinone and 6-methyl-2-heptanone were up-regulated in the active CD group [variable importance in projection (VIP) score 2.8, 2.7, 2.6 and 2.4, respectively], while methanethiol, 3-methyl-phenol, short-chain fatty acids and ester derivatives were found to be less abundant (VIP score of 3.5, 2.6, 1.5 and 1.2, respectively). The PLS-DA model also separated patients with small bowel CD from healthy controls and those with colonic CD from UC. In contrast, less distinct separation was observed between active UC, inactive UC and healthy controls.

The authors concluded that analysis of fecal volatile organic metabolites can provide an understanding of gut metabolomic changes in IBD. It has the potential to provide a noninvasive means of diagnosing IBD, and can differentiate between UC and CD. New studies indicates that analyses of vapors from fecal samples can identify volatile metabolites indicative of different types of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. The study was published online on January 25, 2016, in the journal Alimentary Pharmacology & Therapeutics.

Related Links:

University Hospital Southampton
Supelco
PerkinElmer 


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Piezoelectric Micropump
Disc Pump
New
Troponin I Test
Quidel Triage Troponin I Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.